Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide long-acting - AstraZeneca

Drug Profile

Exenatide long-acting - AstraZeneca

Alternative Names: Bydureon; BYDUREON BCise; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 27 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly and Company; Hongkong Sansheng; University Medical Center Hamburg-Eppendorf
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 30 Aug 2018 Registered for Type-2 diabetes mellitus (Adjunctive treatment, Combination therapy) in European Union (SC)
  • 29 Jun 2018 Committee for Medicinal Products for Human Use (CHMP) recommends approval of exenatide long-acting (BYDUREON® BCise™) for the treatment of Type-2 diabetes mellitus
  • 04 Apr 2018 Launched for Type-2 diabetes mellitus (Adjunctive treatment) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top